


MAS GL Sclae at Rest
0
No Glabella Lines
1
Mild Glabella Lines
2
Moderate Glabella Lines
3
Severe Glabella Lines
4
Very Severe Glabella Lines
MAS GL Sclae Dynamic
0
No Glabella Lines
1
Mild Glabella Lines
2
Moderate Glabella Lines
3
Severe Glabella Lines
4
Very Severe Glabella Lines

FIG. 1

FIG. 2



	30 units	45 units	60 units	Placebo
Investigator	87.3	82.5	91.3	5.9
Subject	74.5	72.8	86.4	7.8

(Responder = 2 points reduction in GL severity, using MAS)

FIG. 3




Responder rates (dynamic, 2-point reduction)
over the full study period
(Investigator assessment)
100
80
60
40
20
0
Day 3
Day 7
Day 14
Month 1
Month 2
Month 3
Month 4
Month 5
Month 6
30 units QM1114-DP
45 units QM1114-DP
60 units QM1114-DP
Placebo

FIG. 4



QM1114-DP Composite responder rates				
	30 units	45 units	60 units	Placebo
Day 14	59%	57%	73%	2%
Day 30	58%	58%	73%	4%

FIG. 5

Composite Endpoints
(N.B. GL scales are different)

GM1114 DP Phll				
	30 units	45 units	60 units	Placebo
Day 14	59%	57%	73%	2%
Day 30	58%	58%	73%	4%


Botox US Label Investigator Responder (wrse – not composite		
	Botox	Placebo
Day 30	80%	3%

Dysport US Label		
	Dysport	Placebo
Day 30 (GL-1)	55%	0%
Day 30 (GL-2)	52%	0%
Day 30 (GL-3)	60%	0%

Xeomin US Label		
	Xeomin	Placebo
Day 30 (GL-1)	60%	0%
Day 30 (GL-2)	48%	0%

GL-1, 2 and 3 represent different Phlll studies for Dysport and Xeomin, respectively

FIG. 6



*Within each full treatment group. Non-responders are assumed to have a duration of 0

FIG. 7




FIG. 8A




Injection site pain per site
Injection site pain
100.0%
90.0%
80.0%
70.0%
60.0%
50.0%
40.0%
30.0%
20.0%
10.0%
0.0%
1
2
3
4
5
6
7
8
Site number

FIG. 8B


Number of subjects with ptosis per site
subjects
8
7
6
5
4
3
2
1
0
1
2
3
4
5
6
7
8
Site number



Maximal Frown Lines
Glabellar lines produced by maximal voluntary muscular activity contributing to the presence of the lines
0-None
Relaxed Skin Tension Line -- no wrinkle.
1-Mild
Glabellar depression(s) -- a mild depression(s) in the glabellar area (inter-brow space) surrounded by mild bulging of the glabellar muscles.
2-Moderate
Glabellar groove -- moderate depression(s) of the inter-brow space surrounded by moderate to significant muscle contraction and bulging.
3-Severe
Glabellar furrow -- deep groove(s) in the glabellar area (inter-brow space) surrounded by profound muscle contraction and bulging

FIG. 9A

At Rest Lines
Characterized by muscle activity at the time of evaluation having limited impact on their presence or absence
0-None
Relaxed Skin Tension Line - no wrinkle.
1-Mild
Fine Wrinkle -- a fine linear depression in the skin surface clearly deeper than relaxed skin tension lines and persistent in its presence.
2-Moderate
Dermal crease -- a deep linear depression in the skin surface that is deeper and/or wider than a fine wrinkle distinguishable from a dermal groove by the absence of muscle contractions at rest.
3-Severe
Dermal groove -- a deep linear depression in the skin surface distinguishable from a dermal crease by the presence of persistent muscle contraction or spasm visible when the patient is "at rest."

FIG. 9B

FIG. 10



Day -14 to Day 0
Informed Consent and Screening
Day 0
Obtain Baseline Data and Confirm Eligibility
Screen Failures
Randomization and Treatment (3:1 [active to placebo])
Group 1
QM1114-DP 50 units (225 subjects)
Group 2
Placebo (75 subjects)
Day 7 (+ 1 day)
Day 14 (± 3 days)
Post-treatment Follow-up Visits
Months 1, 2, 3, 4, and 5 (± 5 days)
Post-treatment Monthly Follow-up Visits
Month 6 (± 5 days)
Final Study Visit/ Early Termination

FIG. 11





FIG. 12



1. Alternative injection sites (A) 2. Alternative injection sites (B)
the selection of injection site alternative depended on the LCL exhibited by the subject



Maximum smile
Left LCL, Investigator's assessment
Wrinkle Scores
3.0
2.8
2.6
2.4
2.2
2.0
1.8
1.6
1.4
1.2
1.0
0.8
0.6
0.4
0.2
0.0
DAY - 1
DAY - 2
DAY - 3
WEEK 1 (DAY 7)
WEEK 2 (DAY 14)
WEEK 3 (DAY 21)
WEEK 4 (DAY 28 FU)
Visit
Group:
Pooled Placebo
QM1114-DP 30 units
QM1114-DP 60 units
QM1114-DP 90 units
Right LCL, Investigator's assessment
Wrinkle Scores
3.0
2.8
2.6
2.4
2.2
2.0
1.8
1.6
1.4
1.2
1.0
0.8
0.6
0.4
0.2
0.0
DAY - 1
DAY - 2
DAY - 3
WEEK 1 (DAY 7)
WEEK 2 (DAY 14)
WEEK 3 (DAY 21)
WEEK 4 (DAY 28 FU)
Visit
Group:
Pooled Placebo
QM1114-DP 30 units
QM1114-DP 60 units
QM1114-DP 90 units

FIG. 13A



Rest
Left LCL, Investigator's assessment
Wrinkle Scores
Visit
DAY - 1
DAY - 2
DAY - 3
WEEK 1 (DAY 7)
WEEK 2 (DAY 14)
WEEK 3 (DAY 21)
WEEK 4 (DAY 28 FU)
Group:
Pooled Placebo
QM1114-DP 30 units
QM1114-DP 60 units
QM1114-DP 90 units
Right LCL, Investigator's assessment
Wrinkle Scores
Visit
DAY - 1
DAY - 2
DAY - 3
WEEK 1 (DAY 7)
WEEK 2 (DAY 14)
WEEK 3 (DAY 21)
WEEK 4 (DAY 28 FU)
Group:
Pooled Placebo
QM1114-DP 30 units
QM1114-DP 60 units
QM1114-DP 90 units

FIG. 13B



Maximum smile
Left LCL, Subject's assessment
Wrinkle Scores
Visit
DAY - 1
DAY - 2
DAY - 3
WEEK 1 (DAY 7)
WEEK 2 (DAY 14)
WEEK 3 (DAY 21)
WEEK 4 (DAY 28 FU)
Group:
Pooled Placebo
QM1114-DP 30 units
QM1114-DP 60 units
QM1114-DP 90 units
Right LCL, Subject's assessment
Wrinkle Scores
Visit
DAY - 1
DAY - 2
DAY - 3
WEEK 1 (DAY 7)
WEEK 2 (DAY 14)
WEEK 3 (DAY 21)
WEEK 4 (DAY 28 FU)
Group:
Pooled Placebo
QM1114-DP 30 units
QM1114-DP 60 units
QM1114-DP 90 units

FIG. 14A



Rest
Left LCL, Subject's assessment
Wrinkle Scores
Visit
Group:
Pooled Placebo
QM1114-DP 30 units
QM1114-DP 60 units
QM1114-DP 90 units
DAY - 1
DAY - 2
DAY - 3
WEEK 1 (DAY 7)
WEEK 2 (DAY 14)
WEEK 3 (DAY 21)
WEEK 4 (DAY 28 FU)
Right LCL, Subject's assessment
Wrinkle Scores
Visit
Group:
Pooled Placebo
QM1114-DP 30 units
QM1114-DP 60 units
QM1114-DP 90 units
DAY - 1
DAY - 2
DAY - 3
WEEK 1 (DAY 7)
WEEK 2 (DAY 14)
WEEK 3 (DAY 21)
WEEK 4 (DAY 28 FU)

FIG. 14B



At maximum frown (GL indication) and maximum smile (LCL indication)
Indication: GL, maximum frown, Investigator's assessment
Wrinkle Scores
Group:
Pooled Placebo
QM1114-DP 50/60 units
QM1114-DP 50/90 units
DAY - 1
DAY - 2
DAY - 3
WEEK 1 (DAY 7)
WEEK 2 (DAY 14)
WEEK 3 (DAY 21)
WEEK 4 (DAY 28 FU)
Visit
Indication: LCL (L), maximum smile, Investigator's assessment
Wrinkle Scores
Group:
Pooled Placebo
QM1114-DP 50/60 units
QM1114-DP 50/90 units
DAY - 1
DAY - 2
DAY - 3
WEEK 1 (DAY 7)
WEEK 2 (DAY 14)
WEEK 3 (DAY 21)
WEEK 4 (DAY 28 FU)
Visit

FIG. 15A



Indication: LCL (R), maximum smile, Investigator's assessment
Wrinkle Scores
3.0
2.8
2.6
2.4
2.2
2.0
1.8
1.6
1.4
1.2
1.0
0.8
0.6
0.4
0.2
0.0
DAY - 1
DAY - 2
DAY - 3
WEEK 1 (DAY 7)
WEEK 2 (DAY 14)
WEEK 3 (DAY 21)
WEEK 4 (DAY 28 FU)
Visit
Group:
Pooled Placebo
QM1114-DP 50/60 units
QM1114-DP 50/90 units

FIG. 15A (Cont.)



Rest
Indication: GL, rest, Investigator's assessment
Wrinkle Scores
Visit
Group:
Pooled Placebo
QM1114-DP 50/60 units
QM1114-DP 50/90 units
DAY - 1
DAY - 2
DAY - 3
WEEK 1 (DAY 7)
WEEK 2 (DAY 14)
WEEK 3 (DAY 21)
WEEK 4 (DAY 28 FU)
Indication: LCL (L), rest, Investigator's assessment
Wrinkle Scores
Visit
Group:
Pooled Placebo
QM1114-DP 50/60 units
QM1114-DP 50/90 units
DAY - 1
DAY - 2
DAY - 3
WEEK 1 (DAY 7)
WEEK 2 (DAY 14)
WEEK 3 (DAY 21)
WEEK 4 (DAY 28 FU)

FIG. 15B



Indication: LCL (R), rest, Investigator's assessment
Wrinkle Scores
Visit
DAY - 1
DAY - 2
DAY - 3
WEEK 1 (DAY 7)
WEEK 2 (DAY 14)
WEEK 3 (DAY 21)
WEEK 4 (DAY 28 FU)
Group:
Pooled Placebo
QM1114-DP 50/60 units
QM1114-DP 50/90 units

FIG. 15B (Cont.)



At maximum frown (GL Indication) and maximum smile (LCL Indication)
Indication: GL, maximum frown, Subject's assessment
Wrinkle Scores
Visit
DAY - 1
DAY - 2
DAY - 3
WEEK 1 (DAY 7)
WEEK 2 (DAY 14)
WEEK 3 (DAY 21)
WEEK 4 (DAY 28 FU)
Group:
Pooled Placebo
QM1114-DP 50/60 units
QM1114-DP 50/90 units
Indication: LCL (L), rest, Subject's assessment
Wrinkle Scores
Visit
Group:
Pooled Placebo
QM1114-DP 50/60 units
QM1114-DP 50/90 units

FIG. 16A



Indication: LCL (R), rest, Subject's assessment
Wrinkle Scores
4.0
3.8
3.6
3.4
3.2
3.0
2.8
2.6
2.4
2.2
2.0
1.8
1.6
1.4
1.2
1.0
0.8
0.6
0.4
0.2
0.0
DAY - 1
DAY - 2
DAY - 3
WEEK 1 (DAY 7)
WEEK 2 (DAY 14)
WEEK 3 (DAY 21)
WEEK 4 (DAY 28 FU)
Visit
Group:
Pooled Placebo
QM1114-DP 50/60 units
QM1114-DP 50/90 units

FIG. 16A (Cont.)



Rest
Indication: GL, rest, Subject's assessment
Wrinkle Scores
4.0
3.8
3.6
3.4
3.2
3.0
2.8
2.6
2.4
2.2
2.0
1.8
1.6
1.4
1.2
1.0
0.8
0.6
0.4
0.2
0.0
DAY - 1
DAY - 2
DAY - 3
WEEK 1 (DAY 7)
WEEK 2 (DAY 14)
WEEK 3 (DAY 21)
WEEK 4 (DAY 28 FU)
Visit
Group:
Pooled Placebo
QM1114-DP 50/60 units
QM1114-DP 50/90 units

FIG. 16B



Indication: LCL (L), rest, Subject's assessment
Wrinkle Scores
4.0
3.8
3.6
3.4
3.2
3.0
2.8
2.6
2.4
2.2
2.0
1.8
1.6
1.4
1.2
1.0
0.8
0.6
0.4
0.2
0.0
DAY - 1
DAY - 2
DAY - 3
WEEK 1 (DAY 7)
WEEK 2 (DAY 14)
WEEK 3 (DAY 21)
WEEK 4 (DAY 28 FU)
Visit
Group:
Pooled Placebo
QM1114-DP 50/60 units
QM1114-DP 50/90 units
Indication: LCL (R), rest, Subject's assessment
Wrinkle Scores
Visit
Group:
Pooled Placebo
QM1114-DP 50/60 units
QM1114-DP 50/90 units

FIG. 16B (Cont.)